Percutaneous ablation treatment in metastatic lung tumors: a single-center experience


ERGUN O., Birgi E., Hekimoğlu A., Eraslan Ö., Durmaz H. A., Karaçin C., ...More

Acta Radiologica, vol.64, no.8, pp.2416-2423, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 64 Issue: 8
  • Publication Date: 2023
  • Doi Number: 10.1177/02841851231175657
  • Journal Name: Acta Radiologica
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, Compendex, EMBASE, MEDLINE
  • Page Numbers: pp.2416-2423
  • Keywords: Ablation techniques, interventional radiology, lung neoplasms, metastatic
  • Lokman Hekim University Affiliated: Yes

Abstract

Background: In recent years, many studies have proven that percutaneous thermal ablation is an effective second-line treatment method with low complication rates in early-stage non-small cell lung carcinoma and lung metastases. Radiofrequency ablation and microwave ablation are commonly used for this purpose. Purpose: To evaluate the factors affecting the success of the percutaneous thermal ablation treatment with technical success, complication rates, and long-term follow-up results in metastatic lung lesions. Material and Methods: Computed tomography (CT)-guided percutaneous ablation was performed for 70 metastatic lung lesions in 35 patients (22 men, 13 women; mean age = 61.34 years; age range = 41–75 years). Radiofrequency ablation was performed in 53/70 (75.7%) lesions and microwave ablation in 17/70 (24.3%) lesions. Results: The technical success rate was 98.6%. Median overall survival, progression-free survival, and local recurrence-free survival of the patients were 33.9 months (range=25.6–42.1 months), 12 months (range=4.9–19.2 months), and 24.2 months (range=8.2–40.1 months), respectively. One- and two-year overall survival rates were 84% and 74%, respectively. Median progression-free survival times were 20.3 months and 11.4 months, respectively, according to the number of metastatic lung lesions being single and multiple, and the difference was statistically significant (P = 0.046). According to the number of lesions ≤3 and >3, the difference was also found statistically significant (P = 0.024) (14.3 months and 5.7 months, respectively). Conclusion: In conclusion, CT-guided percutaneous thermal ablation is a safe and effective treatment method in metastatic lung lesions. The number of lesions is the most important factor in predicting treatment success.